Compare CSL & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSL | MDGL |
|---|---|---|
| Founded | 1917 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 12.5B |
| IPO Year | N/A | N/A |
| Metric | CSL | MDGL |
|---|---|---|
| Price | $330.66 | $559.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | $386.67 | ★ $553.08 |
| AVG Volume (30 Days) | ★ 454.8K | 317.0K |
| Earning Date | 02-03-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 17.56 | N/A |
| Revenue | ★ $5,015,100,000.00 | $740,640,000.00 |
| Revenue This Year | $1.01 | $436.04 |
| Revenue Next Year | $2.69 | $53.17 |
| P/E Ratio | $18.85 | ★ N/A |
| Revenue Growth | 0.14 | ★ 864.21 |
| 52 Week Low | $293.43 | $265.00 |
| 52 Week High | $435.92 | $605.00 |
| Indicator | CSL | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 58.53 | 54.32 |
| Support Level | $318.33 | $546.20 |
| Resistance Level | $340.00 | $589.67 |
| Average True Range (ATR) | 7.85 | 20.61 |
| MACD | 2.46 | -6.67 |
| Stochastic Oscillator | 71.15 | 20.49 |
Carlisle Companies Inc is a holding company. The company manufactures and sells single-ply roofing products and warranted systems and accessories for the commercial building industry. The company is organized into two segments including Carlisle Construction Materials and Carlisle Weatherproofing Technologies. The company's product portfolio includes moisture protection products, protective roofing underlayments, integrated air and vapor barriers, spray polyurethane foam and coating systems, and others. The majority of the company's revenue comes from the Carlisle Construction Materials segment, and more than half of the total revenue is earned in the United States.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.